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The National Eye Institute Visual Function
Questionnaire: Experience of the ONTT
Stephen R. Cole, Roy W. Beck, Pamela S. Moke, Robin L. Gal, Danielle T. Long, and
the Optic Neuritis Study Group
PURPOSE. To describe the health-related quality of life, measured with the National Eye Institute
Visual Function Questionnaire (NEI–VFQ), of patients several years after the onset of optic neuritis,
according to their neurologic and visual status; to assess the relationship between the NEI–VFQ
subscales and clinical measures of visual function; and to assess the internal consistency reliability
of the NEI–VFQ subscales.
METHODS. The NEI–VFQ was administered to 244 patients 5 to 8 years after treatment for an episode
of acute optic neuritis as part of the Optic Neuritis Treatment Trial. Visual acuity, visual field,
contrast sensitivity, and color vision were measured at the same time as questionnaire completion.
RESULTS. The NEI–VFQ scores generally were lower than those reported for a disease-free group.
Reported dysfunction was greater when multiple sclerosis was present and when visual acuity was
abnormal, supporting the construct validity of the NEI–VFQ. Rank correlations between the
NEI–VFQ subscales and clinical measures of visual function were moderate at best. Internal
consistency reliability was generally high for most of the NEI–VFQ subscales.
CONCLUSIONS. These findings add support to the use of the NEI–VFQ as a valuable measure of
self-reported visual impairment. (Invest Ophthalmol Vis Sci. 2000;41:1017–1021)
Optic neuritis is an acute inflammatory disease of theoptic nerve, most commonly produced by demyelina-tion. It usually occurs either as a solitary neurologic
finding (referred to as isolated optic neuritis) or in a patient
with known multiple sclerosis (MS). In the former circum-
stance, it often represents a “forme fruste” of MS.1 In most
cases, optic neuritis attacks are unilateral. Vision typically be-
gins to spontaneously improve within days to weeks, and
recovery is nearly complete within 2 to 3 months. However,
even when visual acuity recovers to 20/20, many patients have
lasting symptoms of visual impairment, and abnormalities can
be frequently demonstrated in contrast sensitivity, color vision,
stereopsis, light-brightness sense, the visual field, afferent pu-
pillary reaction, optic disc appearance, and the visual evoked
potential.2–4 Recurrent attacks of optic neuritis either in the
same eye or the fellow eye occur within 5 years in approxi-
mately 30% of patients; the rate is higher in those with MS
(approximately 50%) than in those without MS (approximately
25%).5
The Optic Neuritis Treatment Trial (ONTT), a multicenter
randomized trial funded by the National Eye Institute, found
that (1) treatment with intravenous corticosteroids can accel-
erate visual recovery but does not have an effect on the degree
of permanent visual loss and (2) treatment with oral pred-
nisone does not improve vision and may be associated with an
increased risk of recurrence.5,6
Measurement of health-related quality of life (HRQL) has
become recognized as an important adjunct to clinical out-
come measures in clinical trials. HRQL is the subjective self-
assessment of one’s health status, often partitioned into several
relevant domains, such as physical functioning, emotional well-
being, and social relations. The National Eye Institute sup-
ported the development of the Visual Functioning Question-
naire (NEI–VFQ), an instrument to assess self-reported visual
impairment in studies of vision. Prior studies have reported
results from the NEI–VFQ among patients with age-related
cataracts, age-related macular degeneration, diabetic retinopa-
thy, primary open-angle glaucoma, cytomegalovirus retinitis,
low vision from any cause,7 and glaucoma.8,9
As part of the ONTT, we administered the NEI–VFQ to a
subset of patients 5 to 8 years after study entry. Herein we
report the following: (1) a description of HRQL, measured with
the NEI–VFQ, of patients several years after optic neuritis,
according to their neurologic and visual status; (2) the relation-
ship between the NEI–VFQ subscales and clinical measures of
visual function; and (3) the internal consistency reliability of
the NEI–VFQ subscales.
METHODS
The protocol, baseline characteristics of patients, and ONTT
treatment trial results have been reported previously.3,5,10–13
Briefly, 457 patients between 18 and 46 years of age with acute
unilateral optic neuritis and no indication of a causal systemic
disease other than MS were enrolled. The primary visual out-
come from treatment was assessed after 6 months. Patients
continued to be followed yearly to assess visual and neurologic
courses. The study protocol was approved by the Institutional
Review Board at each clinical center. Written informed con-
sent was obtained from each patient, in adherence with the
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data (i.e., a subscale score was generated when the subject
responded to one or more items from the subscale) provided
similar results (data not shown). In addition to the 51-item field
test version of the NEI–VFQ, we calculated scores for the
25-item version and present limited results using this abbrevi-
ated version.
Statistical Methods
For each NEI–VFQ subscale, we computed a mean and SD, as
well as level-specific mean values and standard deviations by
gender, race group, occupation, and the 3-level ordered cate-
gorical variables for MS/neurologic disability and visual acuity
in the two eyes. We assessed the mean differences in these
ordered categorical variables by a test for trend, as well as using
ANOVA with Dunnett’s multiple comparisons test, which com-
pares each successive level to the lowest.18 Due to the skewed
distributions for the clinical visual function measures, Spear-
man’s rank correlation coefficient, rs,
19 was used to assess the
association of these measures with the NEI–VFQ subscales for
the better eye. Internal consistency reliability was assessed
with Cronbach’s alpha (a)20 for each multi-item subscale. All
analyses were carried out using SAS version 6.1221 on a UNIX
platform.
RESULTS
The 244 patients had an average age of 40 (67) years at the
time of completion of the NEI–VFQ; 79% were female and 88%
were white. At the time of the completion of the NEI–VFQ, 110
of the 244 (45%) patients had been diagnosed as having CDMS.
However, even when CDMS was present, neurologic disability
was generally mild, with only 15% of the 110 patients with
CDMS having an EDSS score . 2.5 (Table 1).
At the time of completion of the NEI–VFQ, most patients
had good vision in both eyes (Table 2). Specifically, 61% had
visual acuity of 20/20 or better in both eyes, whereas only 6%
had visual acuity worse than 20/40 in one eye and only 3 (1%)
patients had acuity worse than 20/40 in both eyes.
TABLE 1. Characteristics of Subjects at Time of Completion of NEI–









Clinically definite multiple sclerosis (CDMS) 110 (45)




Recurrence of optic neuritis in either eye since study
entry 66 (27)
Age is in years, mean (6 SD). Values are n (%).
* 27 missing observations for occupation; nonprofessional in-
cludes clerical workers, sales workers, and students; laborer includes
service workers, craftsmen, operatives, laborers, farmers, and farm
laborers as defined per U.S. Census.
Vision tests, all performed with correction of refractive 
error from a standardized refraction protocol, included the 
following: (1) visual acuity with a retro-illuminated ETDRS 
chart, (2) contrast sensitivity with the Pelli–Robson chart, (3) 
color vision with the Farnsworth Munsell 100-hue test, and (4) 
visual field with the Humphrey Field Analyzer, program 30-2. 
The normal ranges for visual acuity (logMar value , 0.0 (better 
than 20/20) and contrast sensitivity ($line 15) were based on 
normative data collected by the ONTT clinical centers on 
subjects in the age range of the ONTT patients14 for color 
vision (error score # 110) based on published data,15 and for 
visual field m ean d eviation ( $ 23.00) b ased o n unpublished 
normative data collected by the ONTT Visual Field Reading 
Center at the University of California, Davis (Johnson C, un-
published observations, January 1991). Each patient was clas-
sified as having zero, one, or two eyes abnormal with respect 
to visual acuity.
A diagnosis of clinically definite M S ( CDMS) w as made 
when a patient reported new neurologic symptoms consistent 
with demyelination, other than recurrent optic neuritis, lasting 
more than 24 hours that were confirmed by the presence of a 
new neurologic abnormality on examination.16 Neurologic dis-
ability was assessed using the Expanded Disability Status Scale 
(EDSS).17 Each patient was classified a s f ollows: n o CDMS, 
CDMS with EDSS , 3, or CDMS with EDSS $ 3.
Between April 1996 and March 1997 (5–8 years from 
study entry), the 51-item field-test version of the NEI–VFQ was 
included as part of the testing at the annual examination of 244 
patients who had a study visit during this 1-year period at one 
of the study clinical centers. The major reason for noninclusion 
of patients (for 167 [78%] of the 213 nonincluded patients) was 
that they did not have a visit at a study clinic in the time 
window in which the NEI–VFQ was administered: 13 of the 
patients had moved and had ongoing follow-up by a nonstudy 
ophthalmologist, 50 patients discontinued follow-up before 
the inclusion of the NEI–VFQ, and 104 were still in follow-up 
but did not have a visit during the 12 months it was adminis-
tered (visit window for annual visits spanned 16 months). 
Forty-six (22%) patients had an examination at a study clinic 
during the time window of the NEI–VFQ but did not complete 
the NEI–VFQ; we did not collect data on whether the patient 
refused or the clinic neglected to give the questionnaire to the 
patient to complete. The 213 patients who were not included 
were similar to the 244 who were included in gender (75%
versus 79% female, P 5 0.31) but were slightly younger in age 
at the time of entry into ONTT (mean 31 6 6 versus 33 6 7, 
P , 0.01) and were slightly less often white (82% versus 88%, 
P 5 0.05).
To ease the implementation of the NEI–VFQ in the study, 
the questionnaire was self-administered. Clinic staff described 
the questionnaire and how it was to be completed. This was 
reiterated in written instructions, which preceded the ques-
tions.
Subscales, scored 0 to 100 (with 100 indicating highest 
function), were generated for overall health, overall vision, 
difficulty w ith n ear v ision a ctivities, d ifficulty wi th distance 
vision activities, limitations in social functioning due to vision, 
role limitations due to vision, dependency due to vision, men-
tal health symptoms due to vision, future expectations for 
vision, driving difficulties, limitations with peripheral and color 
vision, and pain or discomfort in or around eyes. For analysis, 
when one or more items from a subscale were missing, the 
subscale was considered missing. Analyses using all available
NEI–VFQ Results
The NEI–VFQ subscale mean values did not differ notably by
gender or race group (data not shown). However, those classified
with occupations of “laborer” (see Table 1 footnote) reported
lower mean values for several subscales: general health, 67 versus
73 (P 5 0.05); general vision, 75 versus 80 (P 5 0.05); ocular
pain, 81 versus 88 (P , 0.01); near vision, 85 versus 92 (P ,
0.01); distance vision, 83 versus 90 (P 0.02); mental health: 81
versus 87 (P 5 0.04); role difficulties: 82 versus 92 (P , 0.01); and
peripheral vision, 80 versus 91 (P , 0.01).
With the exception of the NEI–VFQ expectations subscale,
scores among the recovered optic neuritis patients were generally
lower than a disease-free comparison group (Table 3). This dis-
ease-free comparison group consisted of 75 women and 47 men
with a mean age of 59 (614) years who were seen for a screening
dilated eye examination or correction of refractive error.7 The
majority of NEI–VFQ subscales showed more dysfunction with
increased neurologic disability, with the majority of the probabil-
ity values for trend , 0.01 (Table 4). For the majority of the
subscales demonstrating a significant trend, the association was
driven by the highest category of neurologic disability. This is
demonstrated by the significant Dunnett’s multiple comparison
test (which compares each category to the lowest disability
group, Table 4). Similar trends were observed between several
NEI–VFQ subscales and the combined visual acuity variable, with
the majority of the probability values for trend , 0.01 (Table 4).
However, the ocular pain, social, and expectations subscales did
not demonstrate a linear trend with the combined visual acuity
variable. For the combined visual acuity variable, there was no
distinct pattern of the associations being driven by the highest
category of visual dysfunction.
Association of Clinical Visual Function Measures
with the NEI–VFQ Subscales
Rank correlations between the NEI–VFQ subscales and the
clinical vision tests ranged from small to modest (Table 5). A
moderate correlation (r 5 20.30) was evident between visual
acuity and the general vision NEI–VFQ subscale. Also, a mod-
erate correlation (r 5 20.31) was evident between color vision
and both the role difficulties and peripheral vision NEI–VFQ
subscales. There were several correlations for which one
would expect to see at least a moderate association, such as
visual field and the peripheral vision NEI–VFQ subscale (r 5
0.20), color vision and the color vision NEI–VFQ subscale (r 5
20.23), and visual acuity and near (r 5 20.24) and distant (r 5
20.21) activities. Although no strong associations were ob-
served, all these correlations were in the expected direction.
The NEI–VFQ expectations and ocular pain subscales were
both poorly associated with the visual function tests.
Internal Consistency Reliability
With the exception of the vision-specific expectation subscale
(a 5 0.46), all multi-item subscales demonstrated a moderately
strong internal consistency reliability (general health, a 5 0.87;
general vision, a 5 0.74; ocular pain, a 5 0.72; near activities
a 5 0.89; distance activities, a 5 0.89; social functioning, a 5
0.91; mental health, a 5 0.90; role difficulties, a 5 0.90;
dependency, a 5 0.92; driving, a 5 0.86). The average reli-
ability over the 10 multi-item subscales (omitting the visual
expectation subscale) was 0.86.
Abbreviated 25-Item NEI–VFQ
The 25-item abbreviated version of the NEI–VFQ correlated
well with the full 51-item field test version. Spearman rank
correlations between the two versions were as follows: general
health 5 0.94; general vision 5 0.84; near activities 5 0.96;
distance activities 5 0.95; social functioning 5 0.96; mental
health 5 0.92; role difficulties 5 0.96; dependency 5 0.88;
driving 5 0.90. The ocular pain, color, and peripheral vision
subscales are equivalent on the two versions. The internal
consistency reliability attenuated slightly, with an average co-
efficient alpha of 0.78 for the eight computable subscales. The
coefficient alphas for the 25-item version were as follows:
ocular pain 5 0.72; near activities 5 0.85; distance activities 5







(N 5 122) P
General health 72 (18) 75 (17) 0.13
General vision 79 (14) 81 (13) 0.19
Ocular pain 87 (16) 90 (15) 0.09
Near activities 90 (13) 93 (10) 0.03
Distance activities 89 (14) 95 (8) ,0.01
Social functioning 97 (10) 99 (3) 0.03
Mental health 85 (16) 91 (11) ,0.01
Expectations 47 (16) 43 (26) 0.07
Role difficulties 89 (17) 96 (9) ,0.01
Dependency 97 (12) 99 (5) 0.08
Driving 84 (16) 89 (14) ,0.01
Color vision 95 (14) 98 (8) 0.03
Peripheral vision 89 (19) 97 (10) ,0.01
Values are mean 6 SD.
* Missing data: general health 5 1; general vision 5 7; ocular
pain 5 2; near activities 5 25; distance activities 5 19; social func-
tioning 5 9; mental health 5 14; expectations 5 2; role difficulties 5
4; dependency 5 8; driving 5 11; color vision 5 4; and peripheral
vision 5 7.
† Reference group from Mangione et al.7
TABLE 2. Visual Function at Time of Completion of NEI–VFQ
Measure Better Eye Worse Eye
Visual acuity (N 5 244) 2.14 (2.22, 2.06) [16%] 20.06 (2.14, .04) [39%]
Contrast sensitivity (N 5 243) 15 (15, 16) [17%] 14 (13, 15) [58%]
Visual field (N 5 225) 2.05 (21.40, 1.01) [12%] 21.41 (23.92, 2.02) [33%]
Color vision (N 5 234) 55.00 (28.00, 87.00) [18%] 85.50 (46.00, 159.00) [37%]
Values are: median (quartiles) [% abnormal]. Visual acuity measured with a retro-illuminated ETDRS
chart (normal range: logMar value ,0.0, better than 20/20); contrast sensitivity measured with a Pelli–
Robson chart (normal range $ line 15); visual field measured with the Humphrey Field Analyzer (normal
range: mean deviation $23.00); and color vision measured with the Farnsworth–Munsell 100-hue test
(normal range: color vision error score #110).
0.73; social functioning 5 0.78; mental health 5 0.82; role
difficulties 5 0.75; dependency 5 0.92; driving 5 0.65. Coef-
ficient alphas are not available for the single-item subscales
(general health, general vision, color, and peripheral vision).
We assessed the usefulness of the abbreviated NEI–VFQ by com-
paring the rank correlations between this abbreviated version and
the clinical visual function measures to those found with the
51-item NEI–VFQ field test version. In short, the abbreviated
version provided remarkably similar rank correlations (data not
shown), only distinguishable by very slight attenuation on some
subscales for some of the clinical measures.
DISCUSSION
In this cohort of 244 patients who participated in the ONTT,
NEI–VFQ scores obtained 5 to 8 years after study entry, at a time
when maximum recovery had occurred, were generally lower
than those reported for a disease-free group,7 this despite the fact
that the disease-free group was older than the ONTT cohort
(mean 59 versus 40 years in the present study)7 and therefore
might be expected to report more visual dysfunction than a
disease-free group age-matched to the ONTT cohort. Although
comparisons of our cohort with this reference group are not ideal,
we are not aware of available data for a disease-free population in
the same age range as our optic neuritis cohort.
Self-reported dysfunction was greater when MS was
present and when visual acuity was abnormal, supporting the
construct validity of the NEI–VFQ. Internal consistency reliabil-
ity was high for most of the subscales. However, correlations
between the NEI–VFQ subscales and clinical measures of visual
function were moderate at best.
The ability of the NEI–VFQ to distinguish among the
subgroups based on visual acuity in both eyes was impressive,
considering that even when visual acuity was reduced in both
eyes it was generally only a mild decrease (30 of the 38 with
visual acuity worse than 20/20 in both eyes had acuity $ 20/40
in each eye and only 3 had acuity worse than 20/40 in each
eye). The fact that most of the patients had normal or only
mildly abnormal measured visual function may have attenuated
the correlations between the NEI–VFQ subscales and the clin-
ical measures of visual function. The only two subscales that
appeared to be uninformative with respect to the clinical
measures of visual function were the ocular pain and the vision
expectations subscales. Because optic neuritis was not active at
the time of completion of the NEI–VFQ, the ocular pain sub-
scale would not be expected to be meaningfully associated
with severity of disease. Furthermore, that these subscales are
unrelated to visual function does not imply that the subscales
do not capture important independent information that may be
predictive of future disease. The vision expectations subscale
also performed poorly in another recent test of the psychomet-
ric properties of the NEI–VFQ.7
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Health 76 (15)* 69 (18)† 48 (23)† ,0.01 74 (17) 69 (19) 65 (18)† ,0.01
Vision 79 (12) 79 (15) 69 (21)† 0.08 82 (14) 73 (12)† 74 (15)† ,0.01
Pain 89 (12) 86 (20) 78 (23)† 0.02 88 (15) 83 (20) 89 (14) 0.74
Near vision 93 (10) 89 (14)† 78 (25)† ,0.01 93 (11) 84 (17)† 89 (11) ,0.01
Distant vision 90 (12) 88 (14) 71 (25)† ,0.01 91 (13) 83 (15)† 85 (14)† ,0.01
Social 98 (7) 96 (10) 86 (24)† ,0.01 97 (10) 95 (12) 96 (7) 0.27
Mental health 87 (13) 85 (16) 70 (30)† ,0.01 88 (14) 80 (18)† 81 (18) ,0.01
Expectation 45 (16) 48 (14) 50 (19) 0.08 46 (15) 49 (18) 45 (13) 0.91
Role 93 (12) 87 (19)† 71 (28)† ,0.01 91 (16) 86 (20) 85 (18) 0.02
Dependency 98 (12) 96 (11) 90 (21) 0.07 98 (10) 95 (13) 94 (18) 0.04
Driving 85 (15) 85 (15) 70 (28)† 0.05 87 (14) 76 (19)† 82 (15) ,0.01
Color vision 97 (11) 94 (14) 80 (29)† ,0.01 97 (10) 92 (19)† 90 (19)† ,0.01
Peripheral vision 91 (17) 89 (19) 70 (26)† ,0.01 92 (16) 82 (21)† 88 (22) 0.03
20/20 refers to a logMar value of 0.0.
* Each cell provides the mean (SD) for the subscale. Missing data: see footnote to Table 3.
† Mean difference from “No” or “.20/20 in Both Eyes” group significant at P , .05 using Dunnett’s multiple comparison test.
TABLE 5. Spearman Rank Correlations between Clinical Visual











General health 20.11 0.19 20.22 0.20
General vision 20.30 0.23 20.19 0.17
Ocular pain 0.04 0.08 20.14 20.01
Near activities 20.24 0.12 20.26 0.21
Distance activities 20.21 0.20 20.21 0.22
Social functioning 20.08 0.15 20.22 0.16
Mental health 20.16 0.14 20.14 0.21
Expectations 20.08 20.07 0.12 20.10
Role difficulties 20.11 0.21 20.31 0.20
Dependency 20.15 0.19 20.25 0.17
Driving 20.19 0.16 20.05 0.14
Color vision 20.15 0.21 20.23 0.20
Peripheral vision 20.05 0.20 20.31 0.10
Visual acuity: ETDRS logMar score (lower score 5 better visual
function).
Visual field: Humphrey Field Analyzer mean deviation (higher
score 5 better visual function).
Color vision: Farnsworth–Munsell 100-hue test error score (lower
score 5 better visual function).
Contrast sensitivity: Pelli–Robson chart line number (higher
score 5 better visual function).
Missing data for NEI–VFQ subscales: see Table 3. Missing data for
vision tests: visual acuity 5 0, visual field 5 19; color vision 5 10; and
contrast sensitivity 5 1.
self-reported visual impairment. Although it is unlikely that the
NEI–VFQ will have use for diagnosing optic neuritis or determin-
ing how it should be treated, it nevertheless has value for patient
management by providing the clinician with a comprehensive
overview of a patient’s functioning in everyday life.
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The results must be considered in the context of the 
characteristics of the patients who were included in the study. 
The subset of included patients appears to be representative of 
the full ONTT cohort. Although statistically those included 
were slightly older and more often white than those excluded, 
the magnitude of the differences was small and not consequen-
tial. Patients entered into the ONTT were experiencing their 
first e pisode o f o ptic n euritis i n t he s tudy e ye ( although the 
fellow eye could have had prior optic neuritis) and either did 
not have MS or if it was diagnosed it had not been treated 
(which in effect excluded patients who had more than minimal 
MS at the time of entry). Visual recovery from optic neuritis 
occurs fairly rapidly, with almost all recoverable vision 
achieved in the first f ew m onths a fter t he e pisode o f optic 
neuritis. Thus, when the NEI–VFQ was administered, 5 to 8 
years after study entry, the episode of optic neuritis at enroll-
ment was long resolved. During this period, a substantial pro-
portion of the patients had developed MS (45%) and many 
(27%) had experienced at least one recurrence of optic neuri-
tis. Even when either of these had occurred, there was gener-
ally no or only mild neurologic disability at the time of NEI–
VFQ completion, and, as indicated above, visual function in 
both eyes was usually determined to be normal or near normal.
Gutierrez et al.8 reported on the influence o f glaucoma-
tous visual field l oss on HRQL among 147 g laucoma patients 
and 44 normal-vision reference subjects and found that greater 
visual field d efect ( as m easured b y t he A dvanced Glaucoma 
Interventional Study score) in the better eye was significantly 
associated with lower NEI–VFQ subscale scores, with correla-
tions in the 20.2 to 20.35 range. As can be expected, our 
estimates among recovered optic neuritis patients were 
weaker, ranging from 0.12 for rank correlation between visual 
field and the NEI–VFQ near activities subscale to 0.23 for the 
rank correlation with the general vision subscale. Gutierrez et 
al. also reported internal consistency reliabilities ranging from 
0.67 (expectations subscale) to 0.93 (distance vision subscale), 
with 9 of the subscales greater than 0.78, similar to our find-
ings. Parrish et al.9 also reported on the HRQL among these 
same 147 glaucoma patients, finding P earson c orrelations as 
large as 20.60 between the NEI–VFQ subscales and Humphrey 
visual field, and as large as 20.61 between the NEI–VFQ sub-
scales and the AMA visual acuity impairment score. Our largest 
rank correlation was between visual acuity and the NEI–VFQ 
general vision subscale (20.30).
Mangione et al.7 reported on the psychometric properties 
(reliability and validity) of the NEI–VFQ among 598 patients with 
1 of 5 chronic eye diseases (age-related cataracts, age-related 
macular degeneration, diabetic retinopathy, primary open-angle 
glaucoma, and cytomegalovirus retinitis) or low vision from any 
cause. Internal consistency reliability estimates range from 0.66 
(expectations) to 0.94 (near vision), with the majority greater 
than 0.70, again similar to our results among recovered optic 
neuritis patients. There was a trend toward lower mean NEI–VFQ 
subscale scores among cataract and low vision patients compared 
with the normal-vision reference group, similar to our finding of 
lower mean NEI–VFQ subscale scores among those with greater 
MS disability or combined visual acuity.
Although we used the 51-item field-test version of the NEI–
VFQ, similar results were observed when we computed scores for 
the 25-item abbreviated version of the NEI–VFQ. Our findings add 
support for the use of the NEI–VFQ as a valuable measure of
